SUMMARY Of the first 250 heart and 35 heart and lung transplant recipients at Papworth Hospital, Cambridge, who survived for more than one month after transplantation, 217 heart and 33 heart and lung patients were investigated serologically for evidence of Toxoplasma gondii infection. Six patients acquired primary Tgondii infection, most probably from the donor organ. Five patients experienced Tgondii recrudescence, two of whom had recovered from primary infection a few years earlier. Two patients died from primary Tgondii infection and the severity of symptoms in the other patients with primary infection was related to the amount of immunosuppressive treatment. Prophylaxis with pyrimethamine (25 mg a day for six weeks) was introduced for Tgondii antibody negative transplant recipients who received a heart from a T gondii antibody positive donor after the first four cases of primary toxoplasmosis. Ofthe seven patients not given pyrimethamine, four (57%) acquired primary Tgondii infection. This compared with two of the 14 patients (14%) given prophylaxis.
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Toxoplasma gondii is a ubiquitous pathogen. In the United Kingdom about 30% of persons aged 40 years have serological evidence of previous infection.' T gondii infections are usually asymptomatic, but infection may present as a glandular fever-like illness which is usually self-limiting with full recovery. In contrast, primary T gondii infections in immunocompromised persons are generally symptomatic, often presenting as necrotising encephalitis, myocarditis, or pneumonitis.2 There have been many reports of clinical toxoplasmosis in patients with neoplastic disease,3 with the acquired immune deficiency syndrome (AIDS),4 as well as in immunosuppressed recipients of kidney,25 liver,26 heart78 and bone marrow transplants.9 Some of these infections seem to have been acquired from the donated organ5"8 and some follow reactivation of latent T gondii cysts,79 which may lie dormant but potentially active for many years.'' " In some reports, however, the serological findings are insufficient to permit differentiation between primary and reactivated infections.
Having prospectively studied T gondii serological responses in 217 heart and 33 heart and lung transAccepted for publication 14 September 1988 plant recipients at Papworth Hospital, Cambridge, we now provide a detailed account of serological and clinical responses to T gondii primary and recrudescent infection in these patients.
Material and methods
A total of 250 patients received heart and 35 received heart and lung transplants between January 1979 and January 1988. The first 29 of these patients received conventional immunsuppression with azathioprine and prednisolone as well as a prophylactic course of intravenous equine anti-thymocyte globulin (ATG) for 28 days.'2 The next 60 patients received cyclosporin A and low doses of steroids,'3 while the following 60 patients received either this regimen or cyclosporin A and azathioprine. Thereafter, patients received triple treatment with cyclosporin A, prednisolone, and azathioprine. The initial maintenance doses of these three agents were: cyclosporin A 8-10 mg/kg/day so as to maintain whole blood "trough" values at 800-1200 ng/kg/day; azathioprine 1-2 mg/kg/day, to obtain a white cell count of 5-6 x 109/1; heart transplant patients received prednisolone 1 mg/kg/day reducing to-a maintenance dose of 0 25 mg/kg/day after two weeks; while heart and lung transplant patients Toxoplasmosis in heart and heart and lung transplant recipients received prednisolone 375 mg/day for one day. All Transbronchial biopsy specimens were taken as described by Higenbottom et al6 for investigating new and changed pulmonary symptoms in heart and lung transplant recipients.
Results
Two hundred and seventeen heart transplant and 33 heart and lung transplant patients survived for at least one month after transplantation from whom regular serum samples and the respective donor's serum were available. The numbers of donors and recipients who were T gondii antibody positive at the time of transplantation and the numbers of T gondii mismatched patients (antibody negative recipient, antibody positive donor) are shown in table 1. Patients who had no detectable T gondii antibody before transplantation and who subsequently developed T gondii antibody titres were regarded as having primary infections. Six patients in this series acquired primary T gondii infection, probably from the donor's heart. A summary of the antibody responses to infection in these patients is shown in table 2.
Patients who had detectable Tgondii antibody and subsequently had a rise in Tgondii antibody titres were regarded as having recrudescence of T gondii. Five patients showed evidence of Tgondii recrudescence at some time after transplantation. Two patients (cases 3 and 4) had previously acquired primary T gondii infection. A summary of the antibody responses to T gondii recrudescence for the three remaining patients is shown in table 3. A detailed case history for each patient is as follows.
CASE HISTORIES
A 32 year old man (case 1) had received a heart (3) 21 (8 4) *The first seven patients were not given prophylaxis with pyrimethamine; the next 13 patients were.
tThis patient was given prophylaxis with pyrimethamine.
$T gondii antibody negative recipient, antibody positive organ donor.
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Wreghilt, Hakim, Gray, Balfour, Stovin, Stewart, Scott, English, Wallwork transplant. From day 17 he developed intermittent fever and a dry cough, and culture of bronchial washings grew an Enterobacter species. Routine endomyocardial biopsy specimens taken at day 26 showed Tgondii cysts. Sulphadiazine, 1 g four times a day, and trimethoprim, 250 mg twice a day, were given along with oral pyrimethamine, 25 mg twice a day, and folinic acid. Because of deteriorating consciousness, assisted ventilation and subsequently tracheostomy were required. As the patient had not responded to previous treatment, on day 44 spiramycin 1 g, twice a day, and sulphatriad, 500 mg four times a day, were given instead of trimethoprim and sulphadiazine. He made a steady recovery. Sulphatriad treatment was stopped on day 109 and he was discharged.Antitoxoplasma treatment was discontinued at 1 1 months. A blood sample taken two years after transplantation, however, showed a rise in the Tgondii latex agglutination, dye test, and haemagglutination antibody titres, although he was asymptomatic. A 44 year old man (case 5) had received a heart and lung transplant. As he was mismatched for Tgondii he received prophylaxis with pyrimethamine and folinic acid. After five weeks of pyrimethamine he became neutropenic. Treatment with pyrimethamine was therefore stopped. Subsequently, the patient developed CMV infection but symptoms were only mild. He remained well until 14 months after transplantation when a transbronchial biopsy specimen showed evidence of rejection. Immunosuppressive treatment was therefore increased. He subsequently developed a respiratory tract infection with a productive cough and the T gondii latex agglutination test antibody titre rose from < 16 to 1024. The patient received a briefcourse ofpyrimethamine (25 mg a day) and made an uneventful recovery. Tgondii cysts were not found in myocardial biopsy specimens taken on days 17 and 39 after transplantation and transbronchial biopsy specimens taken on days 23 and 54 after transplantation.
A 47 year old man (case 6) had received a cardiac transplant. As he was mismatched for Tgondii, he was given prophylaxis with pyrimethamine and folinic acid. One hundred and fifteen days after transplantation his Tgondii latex agglutination test antibody titre rose from < 16 to 1024. He did not have any symptoms. T gondii cysts were not found in regular myocardial biopsy specimens taken after transplantation.
A 49 year old man (case 7) had been given a cardiac transplant. Seventy five days after transplantation the latex agglutination test titre had risen from 32 to 256, indicating recrudescence of Tgondii. The patient was asymptomatic without fever. T gondii cysts were not seen in routine myocardial biopsy specimens taken after transplantation.
A 50 year old man (case 8) had received a heart transplant. Twelve days after transplantation he had enlarged cervical nodes, arthralgia of ankles and wrists, as well as an erythematous rash. By day 30, a low grade fever had developed. He subsequently developed general malaise and was treated from day 63 with spiramycin (1 g twice a day), sulphatriad (500 mg four times a day), and pyrimethamine (25 mg twice a day). After six weeks his temperature settled and his general condition gradually improved. Treatment with sulphatriad, pyrimethamine, and spiramycin was stopped on days 77, 100, and 115, respectively. Tgondii cysts were not seen in numerous cardiac biopsy specimens taken after transplantation.
A 23 year old woman (case 9) had received a heart and lung transplant. At nine months a mild fever and Wreghitt, Hakim, Gray, Balfour, Stovin, Stewart, Scott, English, Wallwork left lower lobe pneumonia developed, together with a rise in T gondii latex agglutination antibody test titre to 16 000. Treatment with intravenous sulphadimidine, 2 g three times a day, was started. Although the fever settled spontaneously, shortness of breath persisted. Two weeks later treatment was changed to oral pyrimethamine, 25 mg twice a day, and folinic acid, which was given for one month. She developed Pneumocystis carinii infection at 12 months and died with obliterative bronchiolitis 14 months after the operation. Tgondii cysts were not seen in 11 myocardial biopsy specimens taken at regular intervals from day 7 to day 184, nor in transbronchial biopsy specimens taken on days 142 to 334.
Discussion
In this series we disregarded those patients whose serial serum samples showed rising latex agglutination test antibody titres as a result of T gondii antibody passively acquired from blood transfusion, as well as those who had a non-specific rise in latex agglutination test antibody titres concurrently with active CMV infection. These have been reported previously. '9 We have shown that four of seven patients (57%) mismatched for T gondii who did not receive prophylaxis with pyrimethamine developed primary donor acquired T gondii infection.8 In the Stanford series, Luft et al found that three of four (75%) patients mismatched for T gondii developed lifethreatening primary T gondii infection.7 There is therefore general agreement that when patients are mismatched for T gondii, there is a high risk of their developing serious or fatal toxoplasmosis. We have further shown that prophylactic pyrimethamine (25 mg/day for six weeks) prevents or mitigates the effects of T gondii infection in mismatched patients. Two such patients (cases 5 and 6) in this study developed primary T gondii infection despite prophylaxis with pyrimethamine. Case 5, however, received only a five week course of pyrimethamine because of neutropenia. He developed symptomatic T gondii infection 14 months after transplantation, shortly after his immunosuppressive regimen was intensified because ofa rejection episode. The enhancement of the immunosuppressive regimen may have been responsible for the activation of the latent Tgondii in the donor heart, and it may be necessary to give a further prophylactic course of pyrimethamine when rejection episodes necessitate increased immunosuppressive treatment. Case 6 should have received a full course of pyrimethamine, but due to poor compliance, he may not have taken the full course. Primary T gondii infection developed around four months after transplantation. His infection was probably asymptomatic because he had not received enhanced immunosuppressive treatment, and had not experienced episodes of rejection. The primary toxoplasmosis in these two patients had two rather atypical features: infection was noted much later than in the other four patients who did not receive pyrimethamine; and symptoms were mild or absent.
In the first four patients who developed primary T gondii infection symptoms were noted within five weeks of transplantation (on days 17, 20, 22 and 32). The first indication of Tgondii infection in all of them was fever. Three developed respiratory tract symptoms and one had grand mal fits with loss ofconsciousness. In the series reported by Luft et al two patients developed symptoms four to six weeks after transplantation and died.7 One was found to have chorioretinitis six months after transplantation. Four months later he became mentally confused and three brain abscesses were found on a computed tomographic scan. Interestingly, the two patients in our series who died from disseminated Tgondii infection both received an additional course of steroids for the treatment of organ rejection, while the two who survived did not. This increased immunosuppression probably enhanced the severity of disease.
Of the 75 patients in this series who were T gondii antibody positive before transplantation, only three (4%) had genuine rises in latex agglutination, dye test, and haemagglutination test antibodies after transplantation, indicating recrudescence of T gondii. One (case 7) received azathioprine and prednisolone; case 8 was given cyclosporin A and low dose steroids; and case 9 had triple treatment as the immunosuppressive regimen. This incidence of T gondii recrudescence contrasts with that reported by Luft et al,' who reported that 10 (53%) of 19 heart transplant recipients in the Stanford series who were antibody positive before transplantation had serological evidence of T gondii recrudescence after transplantation. Eight (80%) of their 10 patients who received azathioprine had a > four-fold rise in dye test antibody titres compared with only two (25%) of the eight patients receiving cyclosporin A. None of the nine patients in this series, who were Tgondii antibody positive before transplantation and had been given azathioprine and one (5 9%) of the 17 given cyclosporin A, had a subsequent rise in T gondii antibody titre. There does seem to be a discrepancy between the two series which is difficult to explain. It may be that the differences can be attributed to the amounts of immunosuppressive treatment given in the two groups of patients.
None of the patients in the Stanford series developed clinical illness attributable to T gondii recrudescence compared with two ofthe three patients in our series. Interestingly, case 7 did not receive enhanced immunosuppressive treatment as a result of graft rejection, but cases 8 and 9 did at the time their T gondii antibodies increased in titre.
In our series all ofthe patients with primary Tgondii infection who produced an antibody response seroconverted in the latex agglutination, dye test, and haemagglutination tests, produced T gondii-specific IgM, and had demonstrable Tgondii visible in biopsy or necropsy specimens. All of the five patients with T gondii recrudescence showed an antibody response in the latex agglutination, dye test, and haemagglutination tests, but only two (cases 4 and 9) produced a T gondii-specific IgM antibody response. None of these patients had demonstrable T gondii in biopsy specimens taken at any time after transplantation. Luft et al found T gondii-specific IgM in four (40%) of their patients with Tgondii recrudescence,7 which is similar to our findings.
In conclusion, we have found in the Papworth heart transplant series that Tgondii infection is life-threatening only when acquired from the donor organ and that prophylactic pyrimethamine prevents or mitigates the effect of this infection.
